Lake Street initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $16 price target The firm says the company’s anti-inflammation platform utilizes a disease pathway agnostic approach to increase the number and function of regulatory T cells. The evidence supporting a therapeutic anti-inflammatory benefit of Coya’s low dose IL-2 is strong, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Positive Outlook for Coya Therapeutics, Inc. Driven by IND Resubmission and Promising Trial Results
- Coya Therapeutics Holds Annual Stockholders Meeting
- Coya Therapeutics: Strengthened Patent Estate and Upcoming Catalysts Support Buy Rating
- Coya Therapeutics initiated with a Buy at Lucid Capital
- Coya Therapeutics announces issuance of new U.S. patent for IL-2